Ionis Pharmaceuticals, Inc. (IONS)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-07-29) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-04-29) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-02-25) · 99.1 | 8-K (2026-01-12) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-10-29) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-07-30) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-04-30) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-02-19) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-06) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-01) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-07) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-02-21) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-02) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | ||
| Document and Entity Information | ||
| Audit Information | — |
|
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations | ||
| Condensed Consolidated Statements of Comprehensive Income (loss) | — |
|
| Consolidated Statements of Comprehensive Loss | ||
| Consolidated Statements of Stockholders' Equity | ||
| Consolidated Statements of Stockholders' Equity (P) | ||
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Cash Flows (P) | ||
| Notes | ||
| Basic and Diluted Net Income (loss) Per Share | — |
|
| Basic and Diluted Net Loss Per Share | — |
|
| Collaborative Arrangements and Licensing Agreements | ||
| Convertible Debt | — |
|
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Employment Benefits | — |
|
| Fair Value Measurements | ||
| Fourth Quarter Financial Data (unaudited) | — |
|
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Investments | ||
| Legal Proceedings | ||
| Liability Related To Sale of Future Royalties | — |
|
| Long-term Obligations and Commitments | — |
|
| Operating Leases | — |
|
| Organization and Basis of Presentation | — |
|
| Organization and Significant Accounting Policies | — |
|
| Pay Vs Performance Disclosure | ||
| Public Common Stock Offering | — |
|
| Real Estate Transactions | — |
|
| Revenues | ||
| Segment Information | ||
| Significant Accounting Policies | — |
|
| Stock-based Compensation Expense | — |
|
| Stockholders' Equity | — |
|
| Supplemental Financial Data | ||